Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05a203d85ee01909eaf728dc16f0f6cb |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate |
2020-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0132f642c8377fc3e0d189f4038ae1d4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f5401d5734e1abb5f8c9c21eb3fd938 |
publicationDate |
2021-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
AU-2020209500-A1 |
titleOfInvention |
Crystalline form of a CDK inhibitor |
abstract |
The invention relates to a crystalline form of 6-(difluoromethyl)-8- [(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-{[1-(methylsulfonyl) piperidin-4-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one (PF-06873600) free base (Form 1). The invention also relates to pharmaceutical compositions comprising this crystalline form and to methods of using the crystalline form and such compositions for the treatment of abnormal cell growth, such as cancer, in a mammal. Formula (I): |
priorityDate |
2019-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |